Idorsia Pharmaceuticals Ltd.
Clinical trials sponsored by Idorsia Pharmaceuticals Ltd., explained in plain language.
A biopharmaceutical company focused on discovering and developing small-molecule drugs for various diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill aims to bring back color to vitiligo skin Results expected Jun 2027 (estimated)
-
Can continued lucerastat access help fabry patients?
Disease control Expanded accessThis program provides continued access to lucerastat for people with Fabry disease who were previously enrolled in a clinical trial of this drug. The goal is to allow these patients to keep receiving the treatment after the original study was stopped. It focuses on maintaining tr…
Sponsor: Idorsia Pharmaceuticals Ltd. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New registry tracks sleep drug QUVIVIQ in pregnancy
Knowledge-focused Recruiting nowThis study follows about 785 pregnant women with insomnia to see if taking the sleep medication QUVIVIQ affects pregnancy or baby health. Researchers will compare outcomes like birth defects and pregnancy complications between women who took QUVIVIQ and those who used other insom…
Sponsor: Idorsia Pharmaceuticals Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC